drugset / Trial / NCT07074353
Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study enrolled patients with locally advanced rectal cancer. The experimental group received irinotecan liposomes combined with standard total neoadjuvant therapy (TNT), while the control group received standard TNT. The study endpoints were the complete response rate (cCR + pCR), 3-year event-free survival (EFS) rate, and overall survival (OS). The aim was to compare the efficacy and safety of irinotecan liposomes combined with or without standard TNT.
Timeline
- Start
- 2025-07-20
- Primary completion
- 2028-04-01
- Completion
- 2030-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | — | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | Oxaliplatin | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |
Indications
No indication recorded.